Navigation Links
NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
Date:10/2/2007

allel, NicOx and Ferrer jointly presented a series of preclinical results from a novel, high potency, nitric oxide-donating anti-inflammatory compound at the congress, which showed a broader anti-inflammatory activity than commonly used treatments for skin disorders. These results were obtained in a validated preclinical model of skin disorders by following selected biological markers involved in inflammatory pathways (namely pro-inflammatory mediators such as PGE2, cytokines and TNF-alpha). Scientists have proposed a role for nitric oxide in a number of biological processes in the skin.

Antonio Guglietta, Head of Research and Development at Ferrer, commented: "Nitric oxide is thought to play an important role in the physiology of the skin and these new preclinical results suggest nitric oxide-donating anti- inflammatory agents could have improved efficacy over existing treatments. We believe this collaboration with NicOx can lead to the successful development of a more effective and safer treatment for skin disorders."

NOTE: NicOx and Ferrer aim to develop an improved product to treat a range of skin disorders, including Atopic Dermatitis, Psoriasis and Seborrheic Dermatitis, which affect millions of people each year. The severity of these

conditions can vary widely and in the worst cases they can be painful, increase the risk of infection and cause social isolation due to appearance.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development of nitric oxide- donating drugs to meet unmet medical needs. NicOx is targeting the therapeutic areas of inflammation and cardio-metabolic disease. Resources are focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and NCX 4016, in phase 2 for type 2 diabetes.

NicOx has strategic partnerships with some of the world's leading pharmaceutical compani
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
2. The Past, Present and Future of HLA Typing
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014 The global high content screening market ... ,Threat of Obsolescence, wherein technologies as well as their ... biotechnology companies as well as academic and government institutes ... a powerful research tool in drug discovery. The high ... the high content screening market. In high content screening, ...
(Date:10/1/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide and ... markets in the United States , ... agreement with Patterson Veterinary Supply. Patterson ... of Abaxis veterinary products throughout the United ...
(Date:10/1/2014)... BOSTON , Oct. 1, 2014   ... market-leading provider of Anesthesia Information Management Systems (AIMS), ... Systems, LLC , a wholly owned subsidiary of ... healthcare information systems and connectivity solutions.  ... http://photos.prnewswire.com/prnh/20140930/149407 This partnership ...
Breaking Medicine Technology:High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3
... , , , LIBERTYVILLE, Ill., ... today that the Office of Orphan Products Development of the Food ... for the treatment of Spinal Muscular Atrophy. , , ... for Spinal Muscular Atrophy has ever reached the important stage of ...
... , , , ... Forest Laboratories today announced that results of four phase III ... The Lancet showing that roflumilast, a phosphodiesterase 4 ... to severe COPD. , , COPD is ...
Cached Medicine Technology:Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 2Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 3Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 2Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 3Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 4Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 5Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 6Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 7Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 8Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 9
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, ... out all the stops to rescue surgical patients in ... cost of such heroism is questionable, a new study ... better at saving elderly patients with life-threatening complications after ... intensity, said senior author Dr. Amir Ghaferi. He is ...
(Date:10/1/2014)... that more than 80 per cent of bowel cancers ... found that medicines called ,JAK inhibitors, halted tumour growth ... present in more than 80 per cent of bowel ... in clinical trials, for diseases including rheumatoid arthritis, psoriasis, ... the second-most common cancer in Australia with nearly 17,000 ...
(Date:10/1/2014)... Despite a policy focus on expanding access to ... population continues to have significant dental disease. In ... the American Dental Association , researchers from Tufts ... of Dental Medicine report on the first large-scale ... provided by caregivers to adults with developmental disabilities. ...
(Date:10/1/2014)... 01, 2014 Bedros Keuilian is not ... Camp fitness boot camps, he’s also considered the leading ... with sold out business summits, a line of high-demand ... to a recent Spike TV reality show to his ... is the time for personal trainers and fitness business ...
(Date:10/1/2014)... FARMINGTON, Conn. (PRWEB) October 01, 2014 ... its company, including a redefined mission and visual ... the power of partnering with them to create ... more agile brand that focuses on empowering customers ... benefits communications. , The crown jewel of the ...
Breaking Medicine News(10 mins):Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2
... internet about human incidence of bird flu in Quebec is ... ,Dr Patrick Dolce, the man at the helm ... "Everything is false; there is no patient, no nothing." ... devoted to avian flu which had enabled a report of ...
... C last week. Public health department in Toronto has alerted ... contagious and the man who died happened to have frequented ... ,Although only a single case has been notified, owing to ... public to be cautious.,Meningitis C is a contagious disease caused ...
... about memory could offer an early warning system for ... at Rush University Medical Center. The researchers have found// ... changes in the brain related to Alzheimer's disease. Their ... Neurology. ,The researchers looked at the association ...
... for termination of early pregnancies, might be helpful to ... from the University of California, whose work has been ... licensed drug that blocks the hormone progesterone. In pregnancy, ... If it is depleted the developing fetus can get ...
... and colleagues at four other medical centers have launched ... may contribute to early atherosclerosis. ,“If we can ... who have a genetic predisposition to develop atherosclerosis, we ... stroke sooner and more aggressively,” said David Herrington, M.D., ...
... an imbalance in the overall treatment has lead to the ... of effective dietary care are met with. ,According ... not yet analyzed the nutritional value of the diets the ... any miscalculation in their prescription of menus can lead to ...
Cached Medicine News:Health News:Memory Complaints Are Associated With Alzheimer's Disease 2Health News:Memory Complaints Are Associated With Alzheimer's Disease 3Health News:Breast Cancer Prevention Using Abortion Drug Considered 2Health News:Study Underway to Identify Genes Contributing to Heart Attack Risk 2Health News:Hospital Food Needs Improvement to Meet the Nutritional Needs of the Patient 2
2 mm wide curved tip. Round handle....
3 mm disposable Lance blade. Can fit in to the N0521 Storz handle....
Consist of 6 disposable bevel blades (N0522) and chuck handle (0521). Malleable shafts. Designated most popular model or size....
1.5 mm x 12 mm tip. Angled 15 degrees. Teflon coated with diathermy attachment....
Medicine Products: